242 related articles for article (PubMed ID: 38398494)
1. Management of Neuromuscular Blocking Agents in Critically Ill Patients with Lung Diseases.
Iavarone IG; Al-Husinat L; Vélez-Páez JL; Robba C; Silva PL; Rocco PRM; Battaglini D
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398494
[TBL] [Abstract][Full Text] [Related]
2. Sedation and neuromuscular blocking agents in acute respiratory distress syndrome.
Bourenne J; Hraiech S; Roch A; Gainnier M; Papazian L; Forel JM
Ann Transl Med; 2017 Jul; 5(14):291. PubMed ID: 28828366
[TBL] [Abstract][Full Text] [Related]
3. Neuromuscular blockade management in the critically Ill patient.
Renew JR; Ratzlaff R; Hernandez-Torres V; Brull SJ; Prielipp RC
J Intensive Care; 2020; 8():37. PubMed ID: 32483489
[TBL] [Abstract][Full Text] [Related]
4. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults.
Warr J; Thiboutot Z; Rose L; Mehta S; Burry LD
Ann Pharmacother; 2011 Sep; 45(9):1116-26. PubMed ID: 21828347
[TBL] [Abstract][Full Text] [Related]
5. To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome.
Mefford B; Donaldson JC; Bissell BD
Ann Pharmacother; 2020 Sep; 54(9):899-906. PubMed ID: 32111121
[No Abstract] [Full Text] [Related]
6. Paediatric Acute Respiratory Distress Syndrome Neuromuscular Blockade study (PAN-study): a phase IV randomised controlled trial of early neuromuscular blockade in moderate-to-severe paediatric acute respiratory distress syndrome.
Rudolph MW; Slager S; Burgerhof JGM; van Woensel JBM; Alffenaar JC; Wösten-van Asperen RM; de Hoog M; IJland MM; Kneyber MCJ;
Trials; 2022 Jan; 23(1):96. PubMed ID: 35101098
[TBL] [Abstract][Full Text] [Related]
7. Paralytics in critical care: not always the bad guy.
Forel JM; Roch A; Papazian L
Curr Opin Crit Care; 2009 Feb; 15(1):59-66. PubMed ID: 19186410
[TBL] [Abstract][Full Text] [Related]
8. The effect of neuromuscular blocking agents uses in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials.
Lyu T; Lee YS; Dhanvijay S; Freebairn R
Minerva Anestesiol; 2021 Mar; 87(3):341-350. PubMed ID: 33300324
[TBL] [Abstract][Full Text] [Related]
9. Neuromuscular Blocking Agents for ARDS: A Systematic Review and Meta-Analysis.
Torbic H; Krishnan S; Harnegie MP; Duggal A
Respir Care; 2021 Jan; 66(1):120-128. PubMed ID: 32843506
[TBL] [Abstract][Full Text] [Related]
10. Neuromuscular blockers in the acute respiratory distress syndrome: A meta-analysis.
Hua Y; Ou X; Li Q; Zhu T
PLoS One; 2020; 15(1):e0227664. PubMed ID: 31961896
[TBL] [Abstract][Full Text] [Related]
11. Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient.
deBacker J; Hart N; Fan E
Chest; 2017 Mar; 151(3):697-706. PubMed ID: 27818334
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular blocking agents for acute respiratory distress syndrome: an updated meta-analysis of randomized controlled trials.
Zheng Z; Jiang L; Zhang S; Guervilly C; Zhang M; Feng X; Ding J
Respir Res; 2020 Jan; 21(1):23. PubMed ID: 31931794
[TBL] [Abstract][Full Text] [Related]
13. Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression.
Shao S; Kang H; Tong Z
BMJ Open; 2020 Nov; 10(11):e037737. PubMed ID: 33444180
[TBL] [Abstract][Full Text] [Related]
14. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
Needham CJ; Brindley PG
Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
[TBL] [Abstract][Full Text] [Related]
15. A fresh look at paralytics in the critically ill: real promise and real concern.
Price D; Kenyon NJ; Stollenwerk N
Ann Intensive Care; 2012 Oct; 2(1):43. PubMed ID: 23062076
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular Blockade in the Pre- and COVID-19 ARDS Patients.
Tsolaki V; Zakynthinos GE; Papadonta ME; Bardaka F; Fotakopoulos G; Pantazopoulos I; Makris D; Zakynthinos E
J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143323
[TBL] [Abstract][Full Text] [Related]
17. Myorelaxants in ARDS patients.
Hraiech S; Yoshida T; Annane D; Duggal A; Fanelli V; Gacouin A; Heunks L; Jaber S; Sottile PD; Papazian L
Intensive Care Med; 2020 Dec; 46(12):2357-2372. PubMed ID: 33159530
[TBL] [Abstract][Full Text] [Related]
18. Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: A multicenter survey.
Torbic H; Bauer SR; Personett HA; Dzierba AL; Stollings JL; Ryder LP; Daniels CE; Caples SM; Frazee EN
J Crit Care; 2017 Apr; 38():278-283. PubMed ID: 28012426
[TBL] [Abstract][Full Text] [Related]
19. The role of neuromuscular blockers in ARDS: benefits and risks.
Hraiech S; Forel JM; Papazian L
Curr Opin Crit Care; 2012 Oct; 18(5):495-502. PubMed ID: 22941207
[TBL] [Abstract][Full Text] [Related]
20. Neuromuscular blocking agents for acute respiratory distress syndrome.
Torbic H; Duggal A
J Crit Care; 2019 Feb; 49():179-184. PubMed ID: 30396789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
